Thank you for submitting an application to list the Company’s common stock on The . If you have questions about the status of this application, please contact your listings analyst, , at or via email at . In connection with such application and in accordance with Marketplace Rule 5205(e), Staff has the following requests:

**COMPANY INFORMATION**

Company Name *
Symbol

If this form should be shared with any contacts other than the names included in the Listing Application, please provide the information below. Please note, these individuals will have full access to the Company’s Comment Letter.

<table>
<thead>
<tr>
<th>Company Contact</th>
<th>Outside Legal Counsel</th>
<th>U.S. Business Hours Contact (if company is located outside of the U.S.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Firm Name *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email *</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ISSUE SPECIFIC INFORMATION**

Enter the issue-specific information below for all securities expected to be listed:

**NOTE: Once an Issue is added below it cannot be deleted. Please uncheck the box below if issue will no longer be listed.**

Add New Issue

Indicate Issue to list
Issue Type *
Issue Class
Reserved Trading Symbol *
CUSIP *
Par Value
Par Value Currency
Unit Components
Timing of Unit Separation
Expiration Date of Warrants
In connection with the offering, please provide:

Is the company listing in conjunction with a public offering?  

Yes  

No

Minimum Offering Price per security: $(FAQ)

Number of securities outstanding immediately prior to the offering:

Plus minimum number of securities expected to be sold in the public offering by the Company:

Minimum number of securities expected to be sold in the public offering by Selling Shareholders: *

Plus number of securities expected to be issued in connection with conversions or financings prior to listing:

Total number of securities outstanding immediately after the offering:

Less maximum number of securities to be sold through a directed share program:

Less maximum number of securities to be sold to insiders (including indications of interest):

Less total number of securities held by insiders and/or restricted under Nasdaq Rule 5005(a)(38) outstanding immediately after the offering, not included above:

Total number of unrestricted publicly held securities outstanding immediately after the offering:

Confirm the minimum number of unrestricted Round Lot Holders:

Confirm the minimum number of Round Lot Holders that will hold unrestricted securities with a minimum value of $2,500:

For American Depositary Shares (ADS):

List the name of the Depositary Bank:

Provide the ratio of Underlying Shares (ADS:Shares):

Total number of Underlying Shares Outstanding after offering:

Total number of Underlying Shares Sold in the Offering:

OFFERING INFORMATION

1. Type of Offering:  

2. Expected effective date of registration statement:

3. Expected Date of Initial Trading: *

4. Will delivery of stock certificates be within two business days of initial inclusion on Nasdaq (T+2)?  

Yes  

No

5. Will the stock certificates contain any restrictive legends?  

Yes  

No
INVESTMENT BANKER

<table>
<thead>
<tr>
<th>Lead Underwriter</th>
<th>Underwriter 2</th>
<th>Underwriter 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Firm Name</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary Contact</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Telephone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AUDITOR

<table>
<thead>
<tr>
<th>Firm Name</th>
<th>City</th>
<th>State</th>
<th>Country</th>
</tr>
</thead>
</table>

Transfer Agent

Firm Name

ADDITIONAL INFORMATION

Provide the date that the Company paid the initial application fee:

Provide the date that the Company began its current operations:

Exact reverse stock split ratio:

Expected date that the reverse stock split will be effective:

New CUSIP number:

Provide a list of any and all bridge financings, shelf registrations, Regulation S offerings, or private placements consummated within the prior six months. Describe the transactions in detail (i.e., date, price per share, discount, terms of conversion, the investors and their relationship to the Company or other participants in the transactions), including the terms and conditions of any resale restrictions.

Has the company or any of its predecessors previously applied or requested a review of eligibility to have its securities listed or quoted on any marketplace? If so, please provide the name of the marketplace, and the date and outcome of the application or review. In addition, state whether the company's securities have ever been delisted; the date and reasons for any delisting; whether the issuer is (was) the subject of any inquiries or investigations by a securities
exchange; and the outcome or resolution of such inquiries or investigations. Please note that the issuer’s obligation to respond to this question is ongoing and the issuer must promptly advise the Exchange of receipt of any relevant inquiry.

Confirm whether the company has or plans to become public by combining with a public shell, whether through a reverse merger, exchange offer, or otherwise.

- **Yes**
- **No**

If "yes", please provide a detailed description of the transaction including the names of all parties to the transaction, the terms of the transaction and the date or expected date of closing.

Discuss whether the Company expects that the going concern opinion will be lifted for the next fiscal year end. Indicate whether the Company has discussed this issue with its auditors.

Staff notes the material weaknesses disclosed in the Company's recent SEC filings. Please provide the Company's plan of remediation concerning those weaknesses.

Confirm that the Company's Related Party Transactions were all negotiated at arm's length.

- **Yes**
- **No**

If "no", please provide a detailed description of the transaction including the names of all parties to the transaction and the terms of the transaction:

The PCAOB inspection of the Company's auditor noted "audit deficiencies". Confirm whether any of these deficiencies related to the Company's audit.

- **Yes**
- **No**

Confirm whether the cashless exercise feature of any currently outstanding warrants, or warrants expected to be outstanding, could result in the issuance of common stock if the market price of the common stock is less than the exercise price at the time of exercise (i.e. can the warrant be exercised on a cashless basis if the warrant is “out of the money” and result in the issuance of shares).

- **Yes**
- **No**

If “yes”, please explain:

Confirm that the Company has made all certifications to the SEC required to date under sections 302 and 906 of the Sarbanes-Oxley Act.

- **Yes**
- **No**
Confirm the Company's auditor reviews its quarterly filings in compliance with SAS 100.

- Yes
- No

**Attach Supporting Additional Information Documents**

To facilitate the review process, please submit supporting documentation electronically. You can submit additional documentation for your form at any time during the review process.

No files attached

**REGULATORY PROCEEDINGS/LITIGATION**

1. With respect to the company, its predecessors and its subsidiaries, provide a detailed description of all inquiries, investigations, lawsuits, litigation, arbitration, hearings, or any other legal or administrative proceedings commenced within the past 10 years:
   
   a. that are or were initiated or conducted by any regulatory, civil or criminal agency (including but not limited to the SEC, FINRA, PCAOB, state securities, banking and insurance regulators, Commodities Futures Trading Commission, Department of Justice, state bar associations, state boards of accountancy, or any foreign regulatory, civil or criminal authority); or
   
   b. in which claims material to the company are or were asserted under federal and/or state securities, banking, insurance, tax or bankruptcy laws; or
   
   c. in which claims material to the company are or were asserted otherwise alleging fraud, deceit or misrepresentation. To the extent that such items have been disclosed in the company's SEC filings, the applicant may refer to and/or submit copies of the relevant SEC's filings in which such matters were disclosed in lieu of providing a detailed description.
   
   d. In connection with all proceedings that have been concluded, please provide documentation, which reflects the final disposition of each proceeding. The company should update Staff promptly of any and all material developments related to the matters identified in the response to these questions and should supplement its response if additional matters arise while its application is pending.

2. With respect to current executive officers, directors, and ten percent or greater shareholders, provide a detailed description of all inquiries, investigations, lawsuits, litigation, arbitration, hearings, or any other legal or administrative proceedings:
   
   a. that are or were initiated or conducted by any regulatory, civil or criminal agency (including but not limited to the SEC, FINRA, PCAOB, state securities, banking and insurance regulators, Commodities Futures Trading Commission, Department of Justice, state bar associations, state boards of accountancy, or any foreign regulatory, civil or criminal authority); or
b. in which claims are or were asserted otherwise alleging fraud, deceit or misrepresentation and seeking damages in excess of $100,000.

Upon review of the information provided by the applicant, Staff may request additional information, such as copies of all court and administrative filings, and documents, which reflect the substance of the allegations of any proceedings described above, and the sanctions imposed, including but not limited to, complaints, indictments, opinions, orders, final judgments, letters of censure, consents, undertakings and SEC formal orders of investigation.

3. Describe and provide all documents related to any allegations of fraud or other misconduct brought to the attention of the Company’s management, Board of Directors or Audit Committee related to:

   a. the activities of the Company or its management, employees, Board members or outside advisors and consultants;

   b. the preparation of, or any disclosure made in, the Company’s filings with the Securities and Exchange Commission;

   c. the Company’s internal control over financial reporting. This request encompasses, but is not limited to, any such allegation that can be construed as “whistleblowing” whether by the Company’s employees, its independent audit firm or others.

Attach Supporting Regulatory Documents

To facilitate the review process, please submit supporting documentation electronically. You can submit additional documentation for your form at any time during the review process.

No files attached

BOARD MEMBER AND COMMITTEE INFORMATION

Incomplete information or inaccurate spelling can delay processing of your application so please ensure that all names entered reflect the person’s full legal name and are spelled correctly.

Add a New Director

Number of Directors on Board: 0
Number of Directors on Audit Committee: 0
Number of Independent Directors on Board: 0
Number of Independent Directors on Audit Committee: 0

Provide updates to the information above for any changes in the composition of the board and committees, as necessary. Provide an updated response to the “Regulatory Proceedings/Litigation” section of the listing application for each new director that is added during the review process.
1. Confirm that all planned board committees will be in place prior to listing on Nasdaq.  
   If "No," please explain.

2. Regarding the observers to the Board, please confirm, if applicable:
   a) the observer(s) is/are not voting members:  
      - Yes  
      - No  
      - N/A
   b) the observer(s) is/are not present for executive sessions:  
      - Yes  
      - No  
      - N/A
   c) the observer(s) is/are not present during voting:  
      - Yes  
      - No  
      - N/A
   d) the observer(s) may be dismissed at any time by the committees:  
      - Yes  
      - No  
      - N/A

3. Confirm that the Company’s formal written charter or board resolution addressing the nominations process will be adopted prior to listing.  
   If "No," please explain.

4. Confirm that the Company’s Audit Committee charter will be adopted prior to listing.  
   If "No," please explain.

5. Does any member of the Audit Committee own 10% or more of the Company’s voting power?  
   If “yes”, note that any member of the Audit Committee who owns 10% or more of the Company’s voting power doesn’t fall under the Safe Harbor Provision of SEC Rule 10A-3. Staff recommends that the Company discloses that fact if the Company has an Audit Committee member as such.

**EXECUTIVE OFFICER INFORMATION**

Provide the full legal name (first, middle and last), date of birth or age for each of the Company’s executive officers who are not also directors.

<table>
<thead>
<tr>
<th>First Name</th>
<th>Middle Name</th>
<th>Last Name</th>
<th>Age</th>
<th>Age As of</th>
<th>Birth Date</th>
<th>Gender</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chief Executive Officer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chief Financial Officer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Please note that SEC rules and the Sarbanes-Oxley Act impose heightened obligation on the CFO of a public company, including the requirement to certify the company’s periodic financial statements. Given the importance of this role and the complexities of the accounting rules and practices related to ongoing businesses operations, Nasdaq expects listed operating companies to employ a full-time CFO.

Please submit these materials and information as soon as possible. Staff may request additional information if deemed necessary pursuant to our review of the above. Please note that in addition to the requests above, the Company has a continuing obligation to notify Staff of any material changes to its application. Material changes may include, but are not limited to, changes or proposed changes in ownership/management structure, new financing transactions or proposed financing transactions, or changes in regulatory proceedings/litigation. When possible, please notify Staff in advance of any public filings regarding such changes.

**ATTACH SUPPORTING DOCUMENTS**

In addition to a completed Listing Application, prior to approval, Nasdaq will require additional information and supporting documentation.
Documentation will vary depending on the type of application you are submitting. Please review our Supporting Documentation Guidelines. These guidelines, presented by application type, list the specific documents Nasdaq will require prior to approval for your specific application type. **Required documentation must be provided prior to approval, but is not required at the time of original submission.**

Select documents using the “Browse” button. To attach multiple documents, hold CTRL key while making the selection. Documents should be provided using one of the following formats: MS Word, MS Excel or PDF.

- Submit an executed Listing Agreement through the Nasdaq Listing Center.
- Submit an executed Corporate Governance Certification Form through the Nasdaq Listing Center.
- Submit a copy of the CUSIP Bureau’s confirmation for the securities to be listed.

No files attached

- Provide a written representation from the Company’s lead underwriter that it will place the shares sold in the offering with a sufficient number of holders to meet Listing Rule 5505(a)(3) with at least 300 Round Lot Holders of unrestricted common stock and at least 50% of the 300 required Round Lot Holders will hold unrestricted shares with a value of at least $2,500.

No files attached

- If applicable, submit written confirmation from the company’s transfer agent that the security to be listed is eligible for a Direct Registration Program, or will be on the commencement of trading on Nasdaq.

No files attached

- Submit a letter from the Company’s home country counsel regarding the Company’s reliance on home country practice pursuant to Marketplace Rule 5615(a)(3).

No files attached

- Submit one marked copy of each subsequent amendment to the Company’s registration statement, and the corresponding SEC comment letters and Company’s responses to those comments.

No files attached

- Submit a list of all of the securities currently issued and outstanding (excluding employee stock options) which are exercisable or convertible into the Company’s common stock. Please provide the following for each security:
  a) Number issued and outstanding.
  b) Date of original issuance.
  c) Term sheet or Form of Warrant (as applicable).

No files attached

- Submit a current Broadridge share range analysis and NOBO list for the Company.

No files attached

- Provide a certified list of shareholders of record, as of the date of this letter or more current, provided by the Company’s transfer agent which identifies all shareholders’ names, addresses, and the number of shares held.

No files attached

- Submit updated written correspondence from at least three market makers confirming that they will make a market in the Company’s securities to be listed.

No files attached

- Submit a copy of the Company’s Form 8-A 12b (upon filing with the Securities and Exchange Commission). Please note the Exchange name is “The Nasdaq Stock Market LLC.”

No files attached

**AFFIRMATION**

User Id
Name *
I have been authorized by the Company and have the legal authority to provide information on the Company's behalf; to the best of my knowledge and belief, the information provided is true and correct as of this date; and I will promptly notify Nasdaq of any material changes. I understand that the Company has a continuing duty to update Nasdaq whenever there is an addition to or change in information previously furnished.